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Many forms of heart disease result in the essentially irreversible loss of 
cardiomyocytes. The ability to promote cardiomyocyte renewal may be a promising approach 
to reverse injury in diseased hearts.  
Purpose of Review: To describe the impact of cardiomyocyte cell cycle activation on cardiac 
function and structure in several different models of myocardial disease.   
Recent Findings: Transgenic mice expressing cyclin D2 (D2 mice) exhibit sustained 
cardiomyocyte renewal in the adult heart. Earlier studies demonstrated that D2 mice exhibited 
progressive myocardial regeneration in experimental models of myocardial infarction, and that 
cardiac function was normalized to values seen in sham operated litter mates by 180 days 
post-injury. D2 mice also exhibited markedly improved atrial structure in a genetic model of 
atrial fibrosis. More recent studies revealed that D2 mice were remarkably resistant to heart 
failure induced by chronic elevated afterload as compared to their wild type (WT siblings), with 
a 6-fold increase in median survival as well as retention of relatively normal cardiac function. 
Finally, D2 mice exhibited a progressive recovery in cardiac function to normal levels and a 
concomitant reduction in adverse myocardial remodeling in an anthracycline cardiotoxicity 
model.  
Summary: The studies reviewed here make a strong case for the potential utility of inducing 
cardiomyocyte renewal as a means to treat injured hearts. Several challenges which must be 
met to develop a viable therapeutic intervention based on these observations are discussed.   
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Introduction 
It is largely believed that cardiomyocyte renewal in the adult mammalian heart occurs 
via proliferation of pre-existing cardiomyocytes [1, 2], as opposed to the activity of 
cardiomyogenic stem cells [3, 4]. The intrinsic renewal capacity of adult mammalian 
cardiomyocytes is quite limited, with similarly low rates reported for rodents and humans [5-8]. 
Consequently, injuries causing cardiomyocyte death, as for example myocardial infarction, 
result in reparative fibrosis as opposed to overt tissue regeneration [9]. Fibrosis results in 
stiffening of the myocardial wall, which in turn increases cardiomyocyte stress leading to 
additional cell loss, additional fibrosis and ultimately pump failure. Treatments have 
traditionally relied on interventions aimed at restoring perfusion following acute ischemic 
events, interventions aimed at reducing the vulnerability of at-risk myocardium (as for example 
blocking apoptosis or enhancing angiogenesis), interventions aimed at enhancing contractility 
of the surviving myocardium, and interventions aimed at modulating fibrosis. Advances in our 
understanding of the molecular regulation of cell cycle activity suggest an additional approach, 
namely promoting myocardial regeneration by activating cardiomyocyte renewal. This review 
will focus on a model developed in our laboratory which exhibits increased rates of 
cardiomyocyte cell cycle activity in the adult myocardium. These animals exhibit regenerative 
cardiac growth, with a concomitant improvement in both cardiac architecture and function 
following cardiac injury in a variety of experimental models. 
 
Cyclin D2 expression results in sustained cardiomyocyte cell cycle activity in adult mice 
The notion of inducing cardiomyocyte cell cycle with the hope of driving regeneration of 
the myocardium is not new. Early studies relied on stimulating cell cycle regulatory pathways in 
cultured cardiomyocytes via pharmacologic or genetic intervention [10]. The advent of 
technologies to generate genetically modified animal models harboring either gain-of-function 
or loss-of-functions alterations facilitated studies demonstrating that relatively simple genetic 
changes can result in profound increases in cardiomyocyte cell cycle activity. For example, 
early experiments demonstrated that expression of a powerful cell cycle regulatory molecule, 
the SV40 Large T Antigen protein, was sufficient to induce proliferation of atrial [11, 12] or 
ventricular [13] cardiomyocytes. Subsequently, numerous genetic modifications have been 
shown to impact cardiomyocyte cell cycle activity to varying degrees.  
One such model utilized the alpha cardiac myosin heavy chain transcriptional regulatory 
sequences to target expression of sequences encoding cyclin D2 (Figure 1A, upper panel 
shows a schematic diagram of the transgene) [14]. Cyclin D2 (subsequently designated 
CCND2) is a cofactor which regulates the activity of cyclin-dependent kinase 4 (CDK4), which 
mediates transit through the restriction point of the cell cycle. Targeted expression of cyclin D2 
in adult cardiomyocytes was sufficient to induce expression of endogenous CDK4 (Figure 1A, 
lower left panels). Adult transgenic mice (designated D2 mice) exhibited an approximately 400-
fold increase in the level of ventricular cardiomyocyte S-phase activity as compared to their 
wildtype (WT) siblings, as determined by tritiated thymidine incorporation using a transgenic 
reporter to identify cardiomyocyte nuclei (Figure 1A, lower right panel; thymidine incorporation 
levels were roughly 0.0005% vs. 0.2% for WT vs. D2 mice, respectively, following a single 
injection of isotope).  
Cell cycle activity restores ventricular cardiac structure and function following 
myocardial infarction 
To determine the impact of cardiomyocyte cell cycle activity following ischemic injury to 
the heart, D2 mice and their WT siblings were subjected to permanent coronary artery ligation 
[15]. WT hearts examined at 7 days or 180 days post-infarction exhibited transmural defects 
from the apex to the base (Figure 1B, left; Azan staining, grey indicates scar while magenta 
indicates viable myocardium). D2 hearts harvested at 7 days post-infarction exhibited a similar 
transmural defect as observed in WT mice, indicating that cyclin D2 expression did not bestow 
any cardioprotective activity to acute injury. At 180 days post-infarction, D2 hearts exhibited 
myocardial tissue along the endocardial and epicardial surface of the scar, from the apex to 
the base (Figure 1B, right, see arrows). Because these structures were not apparent in hearts 
at 7 days post-infarction, their presence is indicative of de novo myocardial growth. 
To determine the impact of cardiomyocyte cell cycle activity on cardiac function, D2 
mice and their WT siblings underwent permanent coronary artery ligation or sham surgery, and 
were then subjected to hemodynamic analyses using intracardiac pressure-volume catheters. 
dP/dtmax/EDV, a functional parameter which is not influenced by differences in heart rate, was 
similarly suppressed in infarcted WT and D2 mice as compared to their sham-operated 
controls (Figure 1C; y-axis indicates the percentage normalized to the sham-operated 
animals), in agreement with the similar degree of myocardial injury observed via histologic 
analysis. Cardiac function remained suppressed in the infarcted WT mice at later time points, 
but progressively improved in the infarcted D2 mice. By 180 days post-infarction, cardiac 
function in infarcted D2 mice was not statistically different than that observed in the sham-
operated controls. Thus, cardiomyocyte cell cycle activation can promote both structural and 
functional improvement following myocardial infarction. 
Cell cycle activity restores atrial myocardial structure in a genetic model of fibrosis 
Transforming growth factor (TGF)-β1 is a cytokine which can regulate numerous 
biological activities. Increased TGF-β1 expression is observed following cardiac injuries which 
result in increased myocardial fibrosis. Interestingly, transgenic mice expressing a 
constitutively active form of TGF-β1 in cardiomyocytes (TGF mice) exhibit atrial but not 
ventricular fibrosis (Figure 1D, left panel; red indicates collagen while green indicates viable 
myocardium) [16]. Atrial fibrosis in this model, which was more pronounced in the right atria, 
resulted from TGF-β1-induced cardiomyocyte apoptosis. To determine the impact of 
cardiomyocyte cell cycle activity on atrial fibrosis in this model, TGF and D2 mice were 
intercrossed and the resulting animals analyzed at 12 weeks of age [17]. As expected, right 
atrial cardiomyocyte cell cycle activity was undetectable in the TGF mice; in contrast, tritiated 
thymidine positive right atrial cardiomyocytes were detected in TGF / D2 double transgenic 
mice (1.0 ± 0.3 cells per section). Cardiomyocyte cell cycle activity in the TGF / D2 double 
transgenic animals was accompanied by a marked reduction in right atrial fibrosis as 
compared to mice carrying only the TGF transgene (Figure 1D); interestingly, similar levels of 
myocyte apoptosis were seen in TGF vs TGF / D2 mice, as measured by activated caspase 3 
immune reactivity (0.6 ± 0.31 cells per section vs. 0.83 ± 0.14 cells per section, respectively). 
Thus, cardiomyocyte cell cycle activity can antagonize fibrosis secondary to cytokine-induced 
atrial cardiomyocyte death.       
Cell cycle activity blocks progression to heart failure in a chronic pressure overload 
model 
Chronically elevated afterload (as occurs in hypertension, aortic stenosis or valvular 
disease) induces concentric cardiac hypertrophy, and over time, adverse myocardial 
remodeling and pump failure. Transverse aortic constriction (TAC) is frequently used to model 
chronically elevated afterload in experimental animals. To determine the impact of 
cardiomyocyte cell cycle activity on the progression of heart failure in response to elevated 
afterload, D2 mice and their WT littermates were subjected to TAC surgery [18]. WT mice 
rapidly succumbed to TAC, with 50% of the animals dying within 50 days of surgery, and all 
animals dying within 210 days (Figure 2A). Cardiomyocyte cell cycle activity in D2 mice 
resulted in a 6-fold increase in median survival following TAC, with some mice surviving for as 
long as 450 days post-surgery. Echocardiography revealed that by 10 weeks post-TAC 
surgery, WT mice exhibited decreased left ventricular fractional shortening (Figure 2B) which 
was accompanied with diastolic dilation, both hallmarks for the presence of heart failure. In 
contrast, cardiac function and chamber volume was normal in D2 mice at 10 weeks post-TAC, 
consistent with the markedly enhanced survival of these animals.   
Cardiomyocyte phosphorylated histone H3 (p-H3) immune reactivity was quantitated to 
determine the degree of cell cycle progression (once again a reporter transgene was used to 
identify cardiomyocyte nuclei). Relatively high rates of cardiomyocyte p-H3 immune reactivity 
were seen in the ventricles of D2 sham mice, consistent with the elevated levels of tritiated 
thymidine incorporation described above (note that the temporal duration of S-phase is 
approximately 20-fold longer than M-phase, accounting for the difference in the absolute levels 
of tritiated thymidine incorporation vs. p-H3 immune reactivity). Interestingly, an almost 3-fold 
increase in p-H3 immune reactivity was seen in D2 TAC mice, indicating that the injury 
enhanced cell cycle activity in this model. Analysis of dispersed cell preparations revealed that 
more cardiomyocytes were present in D2 sham hearts as compared to WT sham hearts when 
analyzed at 10 weeks post-surgery, consistent with the presence of sustained cell cycle activity 
in the D2 hearts (Figure 2D). Moreover, more cardiomyocytes were present in D2 TAC hearts 
as compared to the D2 sham hearts, consistent with the injury-induced increase in p-H3 levels. 
Reduced levels of cardiomyocyte apoptosis (Figure 2E) and reduced levels of myocardial 
fibrosis (Figure 2F) were observed in D2 TAC hearts as compared to WT TAC hearts. Thus, 
cardiomyocyte cell cycle activity can reduce adverse remodeling and antagonize heart failure 
progression in response to chronically elevated afterload. 
Cell cycle activity restores cardiac function in a juvenile anthracycline cardiotoxicity 
model 
Although anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin are 
potent anti-cancer chemotherapeutics, their use is limited due to rather severe cumulative 
dose-dependent cardiotoxic side effects. Juvenile patients are particularly sensitive to 
anthracycline-induced cardiotoxicity. To determine the impact of cardiomyocyte cell cycle 
activity on anthracycline-induced cardiotoxicity, juvenile (2 week old) D2 mice and their WT 
littermates received 5 weekly injections of doxorubicin (DOX) or saline, and cardiac function 
was interrogated via echocardiography at 1, 9 and 13 weeks after the last DOX treatment 
(corresponding to 7, 15 and 19 weeks of age) [19]. Cardiac function was similar and stable in 
saline-treated WT and D2 mice (Figure 3A). DOX treatment resulted in a marked decrease in 
cardiac function in WT mice at 1 week after the last DOX treatment, and function remained 
suppressed over the duration of the study. Cardiac function was also decreased in D2 mice at 
1 week after the last DOX treatment, but function progressively improved over the course of 
the study and was indistinguishable from saline treated animals by 13 weeks after the last 
DOX injection.   
Histologic analyses were performed at 1 week (designated the acute stage) and 13 
weeks (designated the late stage) after the last DOX treatment. Cardiomyocyte apoptosis was 
quantitated via activated caspase 3 immune reactivity, and cardiomyocyte cell cycle activity 
was quantitated via tritiated thymidine incorporation. To facilitate comparison of cardiomyocyte 
drop-out and cardiomyocyte renewal, the data was normalized to events per mm2 (Figure 3B). 
DOX treatment of WT mice resulted in cardiomyocyte apoptosis during the acute stage, which 
increased by approximately 3-fold in late stage hearts, in agreement with previous studies 
using this juvenile cardiotoxicity model [20]. Essentially no cardiomyocyte cell cycle activity 
was detected in DOX-treated WT hearts in the acute or late stage. Although DOX treatment 
resulted in a similar level of cardiomyocyte apoptosis in acute stage D2 hearts, no increases 
were observed in late stage D2 DOX-treated hearts. As expected, cardiomyocyte cell cycle 
activity was observed in DOX-treated D2 hearts in both the acute and late stage. Of note, the 
number of cell cycle events per mm2 was greater than the number of apoptotic events per mm2 
in the D2 DOX-treated hearts in both the acute and late stages, suggesting a trend toward 
myocardial regeneration despite the presence of on-going cardiomyocyte apoptosis. 
Consistent with this, myocardial fibrosis was markedly reduced in late stage DOX-treated D2 
hearts as compared to late stage DOX-treated WT hearts (Figure 3C). Thus, cardiomyocyte 
cell cycle activity can antagonize adverse remodeling and restore cardiac function following 
anthracycline-induced cardiotoxicity.  
Future considerations 
The studies reviewed above indicate that targeted expression of cyclin D2 is sufficient to 
drive cardiomyocyte proliferation, and more importantly, that the presence of cardiomyocyte 
cell cycle activity has a positive impact on myocardial function and/or structure in a variety of 
injury models. The observation of progressive functional and structural improvement over the 
long-term (i.e., 6 months post-infarct, 10 weeks post-TAC, and 13 weeks post-cardiotoxic drug 
exposure), supports the notion that recovery results from the presence of active proliferation as 
opposed to transgene-mediated cardioprotective activity. Indeed, when considering the 
magnitude of the cell cycle response in D2 mice, one would a priory predict that a long-term 
follow-up would be required to detect a beneficial effect with this model. A caveat of the D2 
model is that transgene expression in the ventricle is activated during the temporal window of 
cardiomyocyte cell cycle withdrawal which occurs in early postnatal life (i.e., expression may 
activate prior to cardiomyocyte terminal differentiation). However, unpublished studies from our 
group demonstrate that de novo activation of cyclin D2 in adult cardiomyocytes using a 
tetracycline-regulated conditional system gives rise to a similar induction of cell cycle activity. 
Moreover, de novo expression of a number of other genes has been shown to activate 
cardiomyocyte cell cycle activity in adults. Thus, there is reasonable evidence supporting the 
general approach of promoting cardiomyocyte renewal as a means to effect repair of injured 
hearts.   
An interesting observation from the experiments reviewed here is that when 
cardiomyocyte renewal rates are similar to drop-out rates (as was seen in the atrial fibrosis, 
TAC and cardiotoxicity studies), the net effect is a marked reduction or absence of overt 
fibrosis. This suggests that the fibrosis normally observed in these injury models arise as a 
compensatory response to cardiomyocyte loss, as opposed to injury-induced activation of 
fibroblast signaling. Interestingly, this view is supported in cases where there is a massive 
acute loss of cardiomyocytes (as was seen in the coronary artery ligation model); although 
overt scar tissue persists, only minimal fibrosis is observed in the de novo myocardium. 
Persistence of an overt scar may reflect the need to retain wall integrity to prevent cardiac 
rupture at early stages post-injury. Although higher rates of cell cycle renewal may reduce 
persistent scar content, it may come at the cost of greater vulnerability to cardiac rupture. The 
potential contribution of a large number of proliferating cells to arrhythmia vulnerability must 
also be considered. Thus, it remains to be seen if slow vs. fast rates of cardiomyocyte renewal 
are ultimately better tolerated when effecting regenerative growth of the myocardium.   
Another consideration for developing cardiomyocyte renewal-based approaches to 
effect cardiac regeneration is the likely need to incorporate cell-type specificity into the 
intervention. Most of the published studies rely on manipulating genetic pathways which can 
induce proliferation in a wide variety of cell types, including cardiomyocytes. It is possible that 
the used of vector systems with a tropism for targeting expression of cardiomyocytes will effect 
some degree of cell-type preference. Use of non-vector based approaches (as for example, 
delivery of RNA which has been modified for enhanced stability) may also be viable, provided 
a sufficient number of cardiomyocytes can be transduced. As work in the field progresses, it is 
possible that regulatory pathways which are intrinsic to and specific for cardiomyocyte renewal 
will be identified. Such pathways could likely be exploited to develop cell-type specific 
interventions. 
In conclusion, the studies reviewed here, as well as many other examples in the 
literature, make a strong case for the potential utility of inducing cardiomyocyte renewal as a 
means to treat injured hearts. Although a number of formidable obstacles must be overcome, 
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Figure 1. Targeted expression of cyclin D2 results in cardiomyocyte cell cycle activity which 
can promote structural and functional recovery following myocardial injury. A. Schematic 
diagram of the MHC-cycD2 transgene (upper panel), and documentation of transgene 
expression (lower left panel, anti-cyclin D2 immune histology, brown signal), endogenous 
CDK4 expression (lower middle panel, anti-CDK4 immune histology, brown signal) and 
cardiomyocyte S-phase activity (lower right panel, tritiated thymidine incorporation in 
cardiomyocyte nuclei, black punctate signal over blue nuclear signal). (Reproduced from: 
Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ: Circ Res. 2005;96(1):110-
8, with permission from Wolters Kluwer Health, Inc.) [14] B. Histologic analysis of WT and D2 
hearts at 7 and 180 days post-infarction, sections sampled at 1 mm intervals from apex to 
base and stained with Azan (magenta indicates viable myocardium, grey indicates scar). 
(Reproduced from: Hassink RJ, Pasumarthi KB, Nakajima H, Rubart M, Soonpaa MH, de la 
Riviere AB et al.: Cardiovasc Res. 2008;78(1):18-25., with permission from Oxford University 
Press) [15] C. Cardiac function (as quantitated by dP/dtmax/EDV) in WT (open bars) and D2 
(solid bars) at 7, 60 and 180 days post-infarction; data is normalized to the percent activity 
observed in sham-operated littermates. (Reproduced from: Hassink RJ, Pasumarthi KB, 
Nakajima H, Rubart M, Soonpaa MH, de la Riviere AB et al.: Cardiovasc Res. 2008;78(1):18-
25., with permission from Oxford University Press) [15] D. Histologic analysis of right atria from 
12 week old TGF (left panel) and TGF / D2 double transgenic (right panel) mice; sections 
were stained with Sirius Red and Fast Green (green indicates viable myocardium, red 
indicates collagen deposition). (Reproduced from: Nakajima H, Nakajima HO, Dembowsky K, 
Pasumarthi KB, Field LJ: Circ Res. 2006;98(1):141-8, with permission from Wolters Kluwer 
Health, Inc.) [17]. 
 
Figure 2. Cyclin D2 expression blocks progression to heart failure in a chronic pressure 
overload model. A. Survival of WT (blue trace) and D2 (red trace) mice following TAC surgery 
(black trace shows survival of sham operated animals). B. Fractional shortening (FS) of WT 
and D2 mice 10 weeks after sham or TAC surgery as measured by echocardiography. C. 
Detection of p-H3 immune reactivity in cardiomyocyte nuclei (left panel, black punctate signal 
over blue nuclear signal) and quantitation of levels in D2 mice 10 weeks after sham or TAC 
surgery. D. Cardiomyocyte number determined from dispersed cell preparations of WT and D2 
hearts 10 weeks after sham or TAC surgery. E. Activated caspase 3-positive cardiomyocytes 
per mm2 tissue in WT and D2 mice at 3 weeks after sham or TAC surgery. F. Histologic 
analysis of WT (left panel) and D2 (right panel) mice 10 weeks after TAC; sections were 
stained with Sirius Red and Fast Green (green indicates viable myocardium, red indicates 
collagen deposition). (Reproduced from: Toischer K, Zhu W, Hunlich M, Mohamed BA, 
Khadjeh S, Reuter SP et al.: J Clin Invest. 2017;127(12):4285-4296, with permission from 
American Society for Clinical Investigation) [18]. 
 
Figure 3. Cyclin D2 expression restores cardiac function in a juvenile anthracycline 
cardiotoxicity model. A. Cardiac function in saline-treated WT (black trace), saline-treated D2 
(magenta), DOX-treated WT (red trace) and DOX-treated D2 (blue trace) mice at various time 
points in the study; vertical arrows indicate the time of saline or DOX injections. B. Quantitation 
of tritiated thymidine incorporation and activated caspase 3 immune reactivity in DOX-treated 
WT and D2 mice at the acute and late stages; results are plotted as events per mm2 to allow 
direct comparison of the results. C. Histologic analysis of acute and late stage WT and D2 
hearts 13 weeks after DOX treatment; sections were stained with Sirius Red and Fast Green 
(green indicates viable myocardium, red indicates collagen deposition). (Reproduced from: 
Zhu W , Reuter S, Field LJ.: Cardiovasc Res. 2019;115(5):960-5, with permission from Oxford 
University Press) [19]. 
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